Cardinal Therapeutics

Cardinal Therapeutics was a private biotechnology company based in Menlo Park, California, focused on developing anti-inflammatory therapeutics derived from amyloid-related research licensed from Stanford investigators. Publicly available historical sources indicate the company was founded in 2008 and is now archived/out of business rather than operating as an active biotech. Its work appears to have centered on therapeutic amyloid peptides or fibrils with potential application in inflammatory and neurologic diseases, including multiple sclerosis models. Very limited public pipeline detail is available, and no evidence of clinical-stage development, commercialization, or a current operating website was found.